Enzo v. Applera et al.
This article was originally published in The Gray Sheet
DNA sequencing technologies and diagnostics firm Enzo Biochem appeals Connecticut federal court's grant of summary judgment in favor of Applera in a patent infringement suit, which dismissed all claims against Applera. Enzo is suing Applera for alleged past infringement of three now-expired patents related to nucleic acid labeling and detection based on the work of Dr. David C. Ward at Yale University. The court ruled that the three patents were invalid because they "fail to provide the public with adequate guidance of what is and what is not covered," and were not novel "because prior scientific publications described the same subject matter." Enzo notes that the ruling relates solely to the three expired patents and is unrelated to its ongoing business or other litigation
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.